Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seebri

- PMLiVE

Novartis reveals full phase 3 results for Enerzair Breezhaler

Asthma treatment received EU approval earlier this week

- PMLiVE

Novartis forms coronavirus alliance with life sciences companies

Partnership will accelerate research with aid of Gates Foundation

- PMLiVE

Merck gets first approval for MET inhibitor tepotinib in Japan

First worldwide approval for MET inhibitor

- PMLiVE

Novartis says data backs safety of on-hold intrathecal Zolgensma

Data also demonstrated 'remarkable' efficacy in SMA type 2

Novartis day

Novartis donates malaria drug for COVID-19 clinical trials

Hydroxychloroquine will be evaluated for efficacy against novel coronavirus disease

Alzheimer’s: the search for a cure

Will Biogen’s aducanumab re-energise the hunt for pharma’s white whale?

- PMLiVE

Novartis launches $20m COVID-19 response fund

Financial grants will be issued to most impacted communities

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Can protein degraders unlock ‘undruggable’ drug targets?

Exploring a new and exciting area of small-molecule drug discovery

- PMLiVE

BMS scores first oesophageal cancer nod for Opdivo in Japan

Approval in Japan comes before US okay

- PMLiVE

Ex-Sandoz exec admits role in generic drug price-fixing plot

Reignites criticism of high drug prices in the US

Novartis day

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

New drug due for launch in Europe in the second quarter

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links